Human interferon omega-1

Identification

Name
Human interferon omega-1
Accession Number
DB05472
Description

Human interferon omega 1 (IFN-omega 1 = IFN-alpha II1) is a recently discovered protein structurally related to IFN-alpha and -beta. It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. There are multiple routes for administration of omega interferon: injection, an implantable subcutaneous drug delivery system, and an oral formulation. It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interferons
Purchasing individual compounds or compound libraries for your research?
Learn More
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Human interferon omega 1
  • IFN-ω
  • IFNW1
  • Interferon omega-1
  • Interferon-omega
  • Omega interferon

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, C).

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Human interferon omega 1 (IFN-omega 1 = IFN-alpha II1) is a recently discovered protein structurally related to IFN-alpha and -beta. It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. The biological activities of IFN-omega 1 and its physiological role are not known to date.

Mechanism of action

Independent studies demonstrate that interferon omega binds to the alpha/beta receptor, but not the interferon gamma receptor.

TargetActionsOrganism
UInterferon alpha/beta receptor 1Not AvailableHumans
UInterferon alpha/beta receptor 2Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Clinical trial results suggested a favorable overall safety profile for interferon omega.

Affected organisms
  • Hepatitis C virus, RSV and other RNA/DNA viruses
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Human interferon omega-1.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Human interferon omega-1.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Human interferon omega-1.
Acetylsalicylic acidThe risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Human interferon omega-1.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Human interferon omega-1.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Human interferon omega-1.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Human interferon omega-1.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Human interferon omega-1.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human interferon omega-1.
AllopurinolThe risk or severity of adverse effects can be increased when Allopurinol is combined with Human interferon omega-1.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P: Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007 Feb;73(2):118-25. Epub 2006 Sep 11. [PubMed:16987555]
  2. Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE: Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 2005 Jan;65(1):23-34. [PubMed:15652968]
  3. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC: Human interferons alpha, beta and omega. Growth Factors. 2004 Dec;22(4):243-51. doi: 10.1080/08977190400000833. [PubMed:15621727]
  4. Adolf GR, Fruhbeis B, Hauptmann R, Kalsner I, Maurer-Fogy I, Ostermann E, Patzelt E, Schwendenwein R, Sommergruber W, Zophel A: Human interferon omega 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochim Biophys Acta. 1991 Jun 13;1089(2):167-74. doi: 10.1016/0167-4781(91)90004-6. [PubMed:1647209]
UniProt
P05000
PubChem Substance
347910159
Wikipedia
IFNW1

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JA...
Gene Name
IFNAR1
Uniprot ID
P17181
Uniprot Name
Interferon alpha/beta receptor 1
Molecular Weight
63524.81 Da
References
  1. Flores I, Mariano TM, Pestka S: Human interferon omega (omega) binds to the alpha/beta receptor. J Biol Chem. 1991 Oct 25;266(30):19875-7. [PubMed:1834641]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
Molecular Weight
57758.24 Da
References
  1. Flores I, Mariano TM, Pestka S: Human interferon omega (omega) binds to the alpha/beta receptor. J Biol Chem. 1991 Oct 25;266(30):19875-7. [PubMed:1834641]

Drug created on November 18, 2007 11:25 / Updated on September 27, 2020 00:14

Drug search 3